Latest round: Series C. Kim Stratton was appointed Chief Executive Officer of Orphazyme A/S, a biopharmaceutical company.
Kim Stratton was appointed Chief Executive Officer of Orphazyme A/S, a biopharmaceutical company, taking up her position on October 1, 2019. She has more than 25 years of global commercial experience in biopharmaceuticals, with previous roles at Shire Pharmaceuticals and Novartis.
Full founder directory · Investor directory · Company funding database · Fundraising library